Application Detail
Description of Medical Service
Imlifidase is a treatment used to prevent the body from rejecting a newly transplanted kidney. It is used before transplantation in people who have antibodies against the donor kidney and are considered ’highly sensitised’ based on a positive crossmatch test. It is a desensitisation treatment, used to convert people from crossmatch positive, to negative and therefore reducing the likelihood of the recipient's body rejecting the donated kidney.Description of Medical Condition
End-stage kidney disease is defined by partial or completely failed kidney function. Patients require regular dialysis or a kidney transplant for survival.Reason for Application
Highly Specialised Therapy-National Health Reform AgreementMedical Service Type
Therapeutic technologyPrevious Application Number/s
1732Associated Documentation
Application Summary and PICO Set
Application Summary (PDF 238 KB)Application Summary (Word 60 KB)
PICO Set (PDF 550 KB)
PICO Set (Word 211 KB)
Consultation Survey
Consultation Survey (PDF 653 KB)Consultation Survey (Word 32 KB)
PASC Consultation
Bypassing PASC
MSAC Consultation
MSAC consultation input closed Friday, 14 June 2024.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
PICO Confirmation
-Assessment Report
-Public Summary Document
Public Summary Document (PDF 806 KB)Public Summary Document (Word 223 KB)